Mutations in BCORCCND2NRAS and XPO1 Predict Clinical Outcomes upon MRD-Guided Venetoclax Plus Ibrutinib in Relapsed and Refractory Chronic Lymphocytic Leukemia

JSON

Brieghel C, Dubois J, Buhl IK, Nasserinejad K, De Rooij D, Nyrén K, Tran HT, Kersting S, Mattsson M, Ranti J, Mous R, Veldhuis GJ, da Cunha-Bang C, Levin MD, Wirta V, Rosenquist R, Kater AP, Niemann CU

Blood 144 (Supplement 1) 586-586 [2024-11-05; online 2024-11-05]

DOI 10.1182/blood-2024-204532

Crossref 10.1182/blood-2024-204532